Federal Circuit Deliberates Teva’s Patent Listings in FDA’s Orange Book: A Legal Precedent on the Horizon?

The Federal Circuit is currently evaluating a nuanced legal issue regarding whether Teva can list its inhaler patents in the FDA’s Orange Book. This debate centers around whether holding a patent for a component, such as a steering wheel, justifies staking a claim on the entire vehicle. During the hearing, three judges aimed to distill the intricacies of the case to its core question. For further insights, visit the Law360 article detailing the judges’ perspectives and the implications for patent law.